Cases & Deals

ScinoPharm enters into strategic alliance with Baxter for generic oncology injectables

Clients ScinoPharm Taiwan, Ltd.

Jones Day advised ScinoPharm Taiwan, Ltd., a leading process R&D and API manufacturer with research and manufacturing facilities in both Taiwan and China, in a strategic alliance with Baxter International to develop, manufacture, and commercialize five injectable cancer drugs, with a current market of $4 billion, with an option to add an additional 15 injectable molecules. Baxter and ScinoPharm will collaborate on product development and manufacturing with Baxter having the right to commercialize the drugs.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.